Best bridging protocols between cycles in 2026 — 10 schemes compared

1. 1. Cruise TRT 100-150 mg/wk for 8-16 wk between blasts — the medicalized bridge

   The most structured and best-studied bridge. Cruise = phase at TRT dose (100-150 mg/wk testosterone) between two blasts (supraphysiological cycles). Total Test stabilized at 600-900 ng/dL, physiological level. Bhasin 2018 frames TRT at these doses; cruise is functionally a continuous TRT. Allows total gain preservation between blasts with controlled risk profile.

   Dose / Duration

   Cruise: Test cypionate or enanthate 100-150 mg/wk in 2 inj for 8-16 wk between blasts. Bloodwork every 3 months (total T, E2, hematocrit, lipids, PSA if >40). hCG 500 IU 2x/wk optional for fertility.

   Target audience

   Users having done 4-6+ cycles, informed decision to abandon natural HPG recovery, accessible medical supervision, fertility not prioritized or managed by hCG. Good choice for users >35.

   Pros

   • + Total gain preservation between blasts
   • + Stable physiological hormonal profile
   • + Scientifically validated (Bhasin 2018)
   • + TRAVERSE study confirms CV safety (Lincoff 2023)
   • + Possible medicalization (legal TRT)

   Cons

   • − Permanent commitment to exogenous testosterone
   • − No more classic PCT: potential HPG recovery lost
   • − Non-negligible annual cost (~$500-1500)
   • − Reduced fertility without hCG
   • − Continuous hematocrit monitoring

2. 2. Cruise 80 mg/wk ultra-low + hCG (250 IU 2x/wk) — the "fertility" cruise

   Ultra-conservative cruise variant oriented toward maximum fertility preservation. Test at subliminal dose (80 mg/wk), total test stabilized at 450-650 ng/dL (low normal). hCG maintains active Leydig cells (Coviello 2005). Allows natural conception even under prolonged bridge. Minimal risk profile.

   Dose / Duration

   Cruise: Test cypionate 80 mg/wk in 2 inj + hCG 250 IU 2x/wk for 8-16 wk between blasts. Sperm analysis every 6 months if parental project.

   Target audience

   Men 25-40 of reproductive age, current or future parental project, partners in pregnancy project, seeking optimal compromise between gains and fertility.

   Pros

   • + Preserved fertility (Wenker 2015)
   • + Stable hematocrit
   • + Preserved lipid profile
   • + Minimal CV risk
   • + Maintained testicular volume

   Cons

   • − Less favorable body composition than standard cruise
   • − Sometimes insufficient subjective energy
   • − Additional hCG cost (~$150-300/yr)
   • − Logistics of additional injections
   • − Modest gain preservation vs standard cruise

3. 3. Cruise Test E 150 mg + hCG + AI — the "optimized" cruise

   'Optimized' cruise with fine E2 adjustment by low-dose AI and testicular preservation via hCG. Suits rapid aromatizers or users with gynecomastia history on prior cycles. Critical ultra-sensitive E2 bloodwork for AI titration (target 25-40 pg/mL).

   Dose / Duration

   Cruise: Test cypionate 150 mg/wk + hCG 500 IU 2x/wk + Anastrozole 0.25 mg E3D for 8-16 wk between blasts. E2 bloodwork at W4, W8, W12.

   Target audience

   Documented rapid aromatizers, gynecomastia history on cycles, seeking fine hormonal optimization, access to regular ultra-sensitive E2 bloodwork.

   Pros

   • + Fertility preservation
   • + E2 control in rapid aromatizers
   • + Optimal hormonal profile
   • + Preserved gains
   • + Suited to gynecomastia history

   Cons

   • − Easy AI overdose (Burnett-Bowie 2009 — bone density)
   • − E2 too low → libido, joints, mood
   • − Additional AI cost
   • − Expensive ultra-sensitive E2 bloodwork
   • − Logistical burden (3 injection types)

4. 4. SARMs bridge (Ostarine 12.5 mg/d for 6-8 wk) — the "light" bridge

   Minimalist bridge post-AAS cycle: Ostarine 12.5 mg/d for 6-8 wk for anti-catabolic effect and modest gain preservation. Dalton 2011 documents +1.2 kg lean mass at 3 mg/d for 12 wk in elderly subjects; at 12.5 mg/d, HPG suppression still significant (myth of 'SARM bridge without suppression' to forget — Bhasin 2009). No complete HPG recovery possible during bridge.

   Dose / Duration

   Bridge: Ostarine 12.5 mg/d for 6-8 wk after AAS cycle PCT. Mini PCT Nolva 20 mg/d for 4 wk at end of bridge.

   Target audience

   Intermediate users hesitating to switch to TRT cruise, seeking a 'light' transition without permanent commitment. Informed decision accepting residual HPG suppression.

   Pros

   • + No injection (oral)
   • + Moderate cost (~$80-150 for 6-8 wk)
   • + Modest anti-catabolic effect (Dalton 2011)
   • + Joint preservation
   • + Lighter than TRT cruise

   Cons

   • − Real HPG suppression anyway at 12.5 mg/d
   • − Delayed HPG recovery vs classic PCT + off
   • − Black-market SARMs: highly variable quality
   • − Limited human studies
   • − Unclear legal status (research chemical)

5. 5. MK-677 25 mg/d bridge for 12-16 wk — the "GH/IGF-1" bridge

   Non-AAS bridge centered on oral GH secretagogue. MK-677 doesn't suppress HPG axis (Nass 2008 — no documented effect on endogenous testosterone). Stimulates GH and IGF-1, supports recovery, deep sleep, and modest body composition. Allows complete HPG recovery in parallel. Suited to users wanting to preserve gains modestly without additional suppression.

   Dose / Duration

   Bridge: MK-677 25 mg/d single evening dose for 12-16 wk between cycles. Glucose monitoring. No specific PCT (not suppressive).

   Target audience

   Users wanting HPG recovery between cycles while preserving general recovery, normal baseline glucose, no strong family oncological history.

   Pros

   • + No HPG suppression (Nass 2008)
   • + Allows complete HPG recovery in parallel
   • + Deep sleep effect
   • + No injection
   • + Solid clinical studies

   Cons

   • − Limited anti-catabolic effect vs SARM/AAS
   • − Disturbed glucose (moderate insulin resistance)
   • − Strongly increased appetite (weight management)
   • − Sometimes marked water retention
   • − Chronic elevated IGF-1 (theoretical oncological risk — Renehan 2008)

6. 6. Continuous Nolvadex 10 mg/d bridge + nutrition — the "natural plus" bridge

   Ultra-conservative bridge: low-dose Nolvadex continuation (10 mg/d) after classic PCT to support LH/FSH during first months off-cycle. No direct anabolic effect. Vermeulen 1978 and Jordan 1993 document tamoxifen effect on HPG axis. Combined with optimal nutrition, sleep and maintained training, allows minimizing gain loss.

   Dose / Duration

   Bridge: Nolvadex 10 mg/d for 8-12 wk after classic PCT (4 wk). Progressive reduction 10 → 5 → 0 mg over 3 wk. Total T + LH bloodwork at W+12 wk.

   Target audience

   Users wanting to minimize health impact between cycles, fertility priority, longevity focus, seeking a 'clean' transition with complete HPG recovery.

   Pros

   • + No additional suppression
   • + Very accessible cost
   • + Easy adherence (1 tablet/d)
   • + Progressive HPG axis support
   • + Compatible with fertility project

   Cons

   • − No direct anabolic effect
   • − Inevitable natural gain loss
   • − Long-term Nolva side effects at low doses moderate
   • − Absent specific bridge studies
   • − Prolonged effect on E2 receptors

7. 7. Proviron bridge 25 mg/d for 8-12 wk — the "SHBG/libido" bridge

   Bridge oriented toward maintenance of subjective quality (libido, energy) without significant HPG suppression. Proviron (mesterolone) modulates SHBG, frees free testosterone, and has a mild antiestrogenic effect. WHO 1989 documents its use in male infertility. No direct anabolic effect but quality of life maintained during transition.

   Dose / Duration

   Bridge: Proviron 25-50 mg/d for 8-12 wk after classic PCT. No specific PCT (minimal suppression).

   Target audience

   Users concerned about libido during off-cycle phase, high baseline SHBG, seeking a bridge without additional anabolic impact but maintained quality of life.

   Pros

   • + Libido preserved during off
   • + Modulates SHBG (available free T)
   • + Mild antiestrogenic effect
   • + Not hepatotoxic
   • + Moderate cost

   Cons

   • − No direct anabolic effect
   • − Black-market Proviron: frequent counterfeits
   • − Variable availability
   • − Limited contemporary studies
   • − Minor HPG suppression at high doses

8. 8. Female HRT-style TRT bridge (10 mg/wk) — the very conservative "micro-bridge"

   Ultra-low bridge using micro-doses of testosterone (5-15 mg/wk SC) only minimally suppressing HPG axis but maintaining androgenic support. Concept borrowed from female testosterone HRT (Davis 2019, out of amplitude of our list). Suited to very sensitive users wanting to minimize TRT commitment. Null anabolic effect but maintained quality of life.

   Dose / Duration

   Bridge: Test cypionate 5-15 mg/wk SC (insulin needle) for 8-12 wk. No post-bridge PCT (minimal suppression).

   Target audience

   Very conservative users, blast & cruise anxiety, seeking 'almost natural' transition with minimal androgenic support. Uncommon approach.

   Pros

   • + Very limited HPG suppression
   • + Minimal cost
   • + Simple logistics (1 inj/wk SC)
   • + Compatible with HPG recovery
   • + Suited to ultra-sensitive

   Cons

   • − Null anabolic effect
   • − Absent specific studies (emerging concept)
   • − Subjective benefits limited at these doses
   • − Little standardized approach
   • − Debated practical relevance

9. 9. Anavar bridge 20 mg/d for 6 wk — the "light oral" bridge

   Oral bridge using moderate-dose Anavar for 6 wk. Strawford 1999 documents modest anabolic effect of oxandrolone (+3 kg in 12 wk at 20 mg/d in HIV). Preserves muscle gains between cycles without injection. Moderate hepatotoxicity (17α-alkylated) — limit to 6 wk max. Degraded lipid profile.

   Dose / Duration

   Bridge: Anavar 20 mg/d for 6 wk after previous cycle PCT. Continuous hepatoprotectors (TUDCA, NAC). Mini PCT Nolva 20 mg/d for 4 wk at end of bridge.

   Target audience

   Intermediate users wanting light oral bridge, solid baseline liver, aesthetic transition between mass cycles. Not in recurrent bridge (hepatic accumulation).

   Pros

   • + Modest anabolic effect (Strawford 1999)
   • + No injection (oral)
   • + Lean mass preservation
   • + Dry and vascular effect
   • + Short cycle — limited commitment

   Cons

   • − 17α-alkylated hepatotoxicity (Niedfeldt 2018)
   • − Degraded lipid profile
   • − High Anavar cost (~$150 for 6 wk)
   • − Black market: frequent counterfeits
   • − Moderate HPG suppression

10. 10. Classic PCT + full off (no bridge) — the "maximum health" option

    Absence of bridge remains the healthiest long-term option: classic PCT (Nolvadex/Clomid) + full off (duration >= on duration) without any substance between cycles. Allows documented complete HPG recovery (Smit 2021 HAARLEM), reversible biological bloodwork, preserved fertility. Inevitable 15-30% gain loss but optimal health profile.

    Dose / Duration

    PCT Nolvadex 40/40/20/20 for 4 wk + full off >= cycle duration. Total T + LH bloodwork at 3 months post-PCT to confirm recovery. No substance during off.

    Target audience

    All users prioritizing long-term health, fertility project, young users (25-35), 'occasional cycle' philosophy rather than blast & cruise. Ideal default option.

    Pros

    • + Complete HPG recovery possible
    • + Reversible biological profile
    • + Preserved fertility
    • + Zero cost during off
    • + Long-term "maximum health" option

    Cons

    • − Inevitable 15-30% gain loss
    • − Difficult psychological transition phase
    • − Energy and libido drop during off
    • − Not suited to in-season competitors
    • − Less "profitable" cycles in short term